companydirectorylist.com  Global Business Directories and Company Directories
Search Business,Company,Industry :


Country Lists
USA Company Directories
Canada Business Lists
Australia Business Directories
France Company Lists
Italy Company Lists
Spain Company Directories
Switzerland Business Lists
Austria Company Directories
Belgium Business Directories
Hong Kong Company Lists
China Business Lists
Taiwan Company Lists
United Arab Emirates Company Directories


Industry Catalogs
USA Industry Directories












Company Directories & Business Directories

RIGEL FORE

PITTSBURG-USA

Company Name:
Corporate Name:
RIGEL FORE
Company Title:  
Company Description:  
Keywords to Search:  
Company Address: 1126 Navalle ct,PITTSBURG,CA,USA 
ZIP Code:
Postal Code:
94565 
Telephone Number: 9254840931 (+1-925-484-0931) 
Fax Number: 9258464665 (+1-925-846-4665) 
Website:
 
Email:
 
USA SIC Code(Standard Industrial Classification Code):
573407 
USA SIC Description:
Computer & Equipment Dealers 
Number of Employees:
 
Sales Amount:
 
Credit History:
Credit Report:
 
Contact Person:
 
Remove my name



copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)









Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Your Subject:
Your Comment or Review:
Security Code:



Previous company profile:
GREENWOOD ROAD PRODUCTIONS
G SUNDARAM
EITH
Next company profile:
MOHSENI ASSOCIATES
HARBOR CONSTRUCTION
LEFT HAND LANE DESIGN










Company News:
  • Pipeline :: Rigel Pharmaceuticals, Inc. (RIGL)
    Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
  • Rigel Pharmaceuticals, Inc. (RIGL)
    Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer
  • Investor Relations :: Rigel Pharmaceuticals, Inc. (RIGL)
    Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases
  • Management Team :: Rigel Pharmaceuticals, Inc. (RIGL)
    Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
  • Join Our Team :: Rigel Pharmaceuticals, Inc. (RIGL)
    Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
  • Who We Are :: Rigel Pharmaceuticals, Inc. (RIGL)
    Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
  • Products :: Rigel Pharmaceuticals, Inc. (RIGL)
    Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
  • Rigel Provides Business Update and 2025 Outlook
    Rigel continues to advance its Phase 1b clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of R289 in patients with relapsed or refractory (R R) lower-risk myelodysplastic syndrome (MDS)
  • Rigel Reports Second Quarter 2025 Financial Results and Provides . . .
    Total revenue and net income are inclusive of $40 million in non-cash contract revenue related to Rigel's agreement with Lilly Conference call and webcast scheduled today at 4:30 p m Eastern Time
  • Rigel Reports Third Quarter 2025 Financial Results and Provides . . .
    Rigel continues to advance its Phase 1b clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of R289 1, a potent and selective dual interleukin receptor-associated kinases 1 and 4 (IRAK1 4) inhibitor, in patients with relapsed or refractory (R R) lower-risk myelodysplastic syndrome (MDS)




Business Directories,Company Directories
Business Directories,Company Directories copyright ©2005-2012 
disclaimer